Nona Biosciences has announced that DualityBio, a collaborator of Nona Biosciences, and BeiGene signed an agreement for BeiGene to buy an exclusive option for a global clinical and commercial license to the antibody-drug conjugate (ADC) programme for patients with select solid tumours.

The investigational, preclinical ADC programme was developed under the partnership agreement started between US-based Nona Biosciences and DualityBio.

Nona Biosciences, a biotechnology company, and DualityBio collaborated in 2022 to help the latter develop the first-in-class ADC.

As part of that cooperation, Nona Biosciences gave DualityBio exclusive rights to its monoclonal antibodies for select tumour types.

Both firms will keep working together as per the terms of the collaboration agreement.

Nona Biosciences has developed a significant amount of knowledge in the ADC field.

The American biotechnology firm has actively built an ADC cooperation ecosystem and worked closely with numerous partners.

Nona has also continuously improved its advanced platform technology in order to fully unleash its innovation potential and accelerate the global development of novel ADC therapeutics.

As one of its primary initiatives, the biotechnology company aims to continue boosting the value of innovation and meet worldwide medical demands while also expanding its networks in ADC innovation.

Nona, a wholly-owned subsidiary of HBM Holdings, is engaged in the production of advanced antibody technology. The company’s solution ranges from target validation and antibody discovery through preclinical research.

DualityBio is a clinical-stage company with a focus on the discovery and development of next-generation ADC therapeutics for patients with autoimmune diseases and cancer.

The company has advanced four assets into global clinical studies. It has also developed more than 10 product candidates that are presently in the preclinical phase.

In May this year, Nona joined forces with ModeX Therapeutics to use the former’s platforms to support the development of ModeX’s multispecific antibody therapeutics.